Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

portfolio strategy

- PMLiVE

Biosimilars: friend or foe for healthcare systems?

An opportunity in Europe, but widespread acceptance and uptake is by no means a done deal

- PMLiVE

Value-based assessment

NICE is set to modify the way it operates, but the changes shouldn’t come as a surprise

Define the patient burden in rare diseases

Putting patients and carers at the heart of the value demonstration equation in orphan drugs is key

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

Orphan indication? No easy access

Health technology assessment for orphan drugs continues to present challenges for pharmaceutical companies

- PMLiVE

Infographic: Orphan drug market

A visual guide to the orphan drug and rare disease market for pharma

Interview: Beate Wieseler, IQWIG

Head of the department of drug assessment at the German HTA body on taking a pragmatic approach to comparing medicines

- PMLiVE

Almirall expands in US via $400m deal to buy Aqua

Will boost its standing in dermatology

- PMLiVE

IMS Health acquires HGS Europe

Founders Graeme and Angela McFarlane bring HGS' market access services to IMS' UK team

Interview: Allan Hillgrove, Boehringer

Boehringer’s head of sales and marketing on access, partnerships and China on an important year for the German pharma company

Putin – pharma’s friend or foe in Russia?

Assessing the opportunities and challenges for pharmaceutical companies entering the Russian market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links